Second death in trial of experimental Alzheimer’s drug raising concerns
Nov 29, 2022
Doctors suspect that by stripping away amyloid deposits, lecanemab weakens blood vessels and leaves them vulnerable to bleeds.
Bipartisan group of 23 state AGs joins call for unrestricted coverage of Alzheimer’s treatments
By
Kimberly Bonvissuto
May 03, 2023
A bipartisan group of attorneys general from 23 states have joined a growing chorus calling on Medicare to reverse a previous decision and provide unrestricted coverage of Food and Drug Administration-approved...
More news for Monday, Feb. 5
By
Kimberly Bonvissuto
Feb 05, 2024
Takeaways from NIC MAP’s fourth-quarter fundamentals release … Use of Medicaid wraparound services by dually eligible individuals varies by service, state … StartUp Health launches global Alzheimer’s...
More news for Monday, Nov. 13
By
Kimberly Bonvissuto
Nov 13, 2023
CareTrust REIT moves forward with ‘foot on the gas’ … Assisted living community pays $59K in back wages, $7K in penalties for repeat wage violations … Coalition of business groups sues...
‘Substantial’ decline in dementia rates due in part to higher education levels: study
By
Kimberly Bonvissuto
Nov 08, 2022
The prevalence of dementia in older adults in the United States declined 30% between 2000 and 2016, possibly due to rising education levels, a reduction in smoking and better treatment of cardiovascular...
More news for Monday, Nov. 7
By
Kimberly Bonvissuto
Nov 07, 2022
HUD opens 5th round of COVID supplemental payments, reduces reimbursements for senior housing … Front Porch expands memory care programs to meet increasing demand … Active adult data now available...
Older adults at risk for dementia see fast declines in household wealth before dementia onset
By
Kimberly Bonvissuto
Sep 19, 2023
Household wealth, especially financial wealth, declines much more quickly among people with probable dementia in the decade before dementia onset compared with older adults without a dementia diagnosis,...
Cognitive impairment delayed with genetic variant
Jun 20, 2024
The onset of cognitive impairment was delayed among those heterozygous for the apolipoprotein E3 Christchurch variant.
Medicare spending would increase $2.0 to $5.1 billion with lecanemab
May 18, 2023
$2.0 to $5.1 billion would include lecanemab and ancillary costs; estimated annual per-patient coinsurance could reach $6,636
Higher triglyceride levels linked to lower dementia risk
Oct 26, 2023
Similar findings were seen in a a subcohort of participants with APOE-ε4 genetic data and in an external validation cohort.